When Should Tysabri Patients Discuss PML Risk with Their Doctor?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may wonder when the risk of progressive multifocal leukoencephalopathy (PML) becomes a concern. Decades of pharmacovigilance have established that PML risk increases with longer treatment duration, particularly beyond two years. This page outlines the timeline of PML development and provides follow-up questions to discuss with your doctor.

Tysabri and PML: Medical Evidence and FDA Warnings

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, cognitive impairment, gait disturbance, and visual changes. Diagnosis relies on brain imaging, typically magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Early recognition is critical because the disease can progress rapidly. The FDA label advises healthcare professionals to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first indication of the infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The pharmacology of Tysabri involves binding to alpha-4 integrins on the surface of immune cells, thereby preventing their migration across the blood-brain barrier. This mechanism reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JC virus to reactivate and cause PML. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JC virus antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. Adverse event reports from the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they underscore the range of neurological symptoms that may overlap with early PML signs, complicating diagnosis.

Legal Considerations for New York Patients: Statute of Limitations

The adequacy of warnings regarding Tysabri and PML is a central concern for affected patients and their attorneys. The FDA boxed warning explicitly states the risk and identifies the three key risk factors. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients are informed and monitored. However, questions may arise about whether the warnings were sufficiently clear or timely, particularly for patients who developed PML after prolonged therapy. For patients in New York who have developed PML after using Tysabri, attorney-related considerations include the statute of limitations for filing a lawsuit. In New York, the statute of limitations for personal injury claims generally is three years from the date of injury, but this can vary depending on the specific circumstances, such as when the injury was discovered or should have been discovered. The timeline between exposure to Tysabri and documented harm is critical. PML typically occurs after months to years of treatment, with risk increasing after two years. This latency period can affect when the injury is recognized and when the statute of limitations begins to run. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadlines. In summary, Tysabri carries a known risk of PML, as detailed in FDA warnings and clinical data. The mechanistic link involves impaired immune surveillance due to the drug's action on integrins. For New York patients, the statute of limitations is a key legal factor, and the timing of PML onset relative to treatment duration is important for both medical and legal assessments. Affected individuals should seek prompt medical evaluation and legal counsel to address their specific situation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. However, for PML caused by Tysabri, the injury may not be discovered immediately due to the latency period. The discovery rule may apply, meaning the clock starts when the injury is or should have been discovered. It is crucial to consult with an attorney to determine the exact deadline for your case.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JC virus antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.